
|Articles|December 12, 2012
Zytiga now available for late-stage prostate cancer
FDA expanded the approved use of abiraterone acetate (Zytiga, Janssen Bioech) to treat men with late-stage castration-resistant prostate cancer prior to receiving chemotherapy.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Targeted Coordination Is Crucial in Boosting Pneumococcal Vaccine Coverage
2
Wegovy Pill Receives FDA Approval as First Oral GLP-1 for Weight-Loss
3
Women’s Health: Top Stories of 2025
4
Q&A: Why Pharmacy Is Incentivized to Eliminate HIV Stigma
5














































































































